Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2636247 | 0.84 | MAPT (0.41) | MAPTFAAH | |
| SCHEMBL1706068 | 0.82 | MAPT (0.41) | MAPTFAAH | |
| SCHEMBL6867730 | 0.80 | MAPT (0.41) | MAPTFAAH | |
| SCHEMBL9517181 | 0.79 | HCAR2 (0.40) | — | |
| SCHEMBL2576621 | 0.79 | MAPT (0.39) | MAPT | |
| SCHEMBL16375095 | 0.77 | MAPT (0.41) | MAPTFAAH | |
| SCHEMBL4252386 | 0.77 | MAPT (0.41) | MAPTFAAH | |
| SCHEMBL14668229 | 0.77 | MAPT (0.41) | MAPTFAAH | |
| SCHEMBL7614587 | 0.77 | MAPT (0.40) | MAPTFAAH | |
| SCHEMBL7007545 | 0.77 | FAAH (0.44) | MAPTFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2480549-B1 | Fused imidazo[3,2-d]pyrazines as PI3 kinase inhibitors | FUNDACIÓN CT NAC DE INVESTIGACIONES ONCOLÓGICAS CARLOS III (ES) | 2015-04-08 | — | — | EP | disclosed |
| US-20130029967-A1 | Fused Imidazo [3,2 - D] Pyrazines as P13 Kinase Inhibitors | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2013-01-31 | — | — | US | disclosed |
| EP-2480549-A1 | FUSED IMIDAZO [3, 2 - D]PYRAZINES AS PI3 KINASE INHIBITORS | Centro Nacional de Investigaciones Oncológicas (CNIO) (ES) | 2012-08-01 | — | — | EP | disclosed |
| WO-2011036461-A1 | FUSED IMIDAZO [3, 2 - D] PYRAZINES AS PI3 KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCΌLOGICAS (CNIO) (ES) | 2011-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029967-A1 | Fused Imidazo [3,2 - D] Pyrazines as P13 Kinase Inhibitors | MTOR, PIK3CA, CDK2 | MAPT 2714/4885FAAH 4365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.